Authors: A Ruggiero G Cefalo ML Garré M Massimino C Colosimo G Attinà I Lazzareschi P Maurizi V Ridola G Mazzarella M Caldarelli C Di Rocco E Madon ME Abate A Clerico A Sandri R Riccardi
Publish Date: 2005/11/15
Volume: 77, Issue: 1, Pages: 89-94
Abstract
Twentyfour patients with a median age of 105 years were enrolled onto this openlabel multicenter phase II study The patients were previously treated with surgical resection 17 of 24 radiotherapy 19 of 24 and chemotherapy 18 of 24 Therapy was administered orally three times a day for 5 consecutive days at the dose of 200 mg/m2/d×5 for chemotherapy naive patients In patients heavily pretreated with chemotherapy the starting dose was of 150 mg/m2/d×5A total of 95 cycles were administered The median progression freesurvival PFS was 3 months for the entire group while disease stabilization was obtained in 7 patients 291 all with supratentorial tumors No CR or PR was observed TMZ treatment showed a limited toxicity Thrombocytopenia was the most common hematological adverse effect
Keywords: